Long-term purchase of sofosbuvir in India price 18710176959 purchase of sofosbuvir

Sofosbuvir (English name br, trade name d) is a new drug developed by Gilead of the United States for the treatment of chronic hepatitis C. It was approved by the U.S. Food and Drug Administration (D) to be marketed in the United States. It was approved by the European Medicines Agency (M) to be marketed in various EU countries on January 1, 2019.
The drug is the first to safely and effectively treat certain types of hepatitis C without the need for interferon. Clinical trials have confirmed that against hepatitis C, the drug combined with pegylated interferon and ribavirin has an overall sustained virological response rate (R) of up to %. Against hepatitis C, the drug combined with ribavirin has an R of %%. For hepatitis C, the R of this drug combined with ribavirin is %%. It is worth mentioning that the clinical trials of sofosbuvir also included some patients with hepatitis C and cirrhosis, and the efficacy was also significant.
1. Clinical Application
Usage and Dosage: One tablet per m, one tablet per day, taken on an empty stomach or with food.
Chronic hepatitis C can be treated in combination with ribavirin or ribavirin + pegylated interferon. The recommended regimen is as follows: treatment regimen for H alone infection or H/H combined infection. Treatment duration: genotype or type sofosbuvir + pegylated interferon h + ribavirin. genotype sofosbuvir + ribavirin Week genotype sofosbuvir + ribavirin weeks.
Patients with chronic hepatitis C who are unable to use interferon may consider using sofosbuvir combined with ribavirin for weekly treatment.
Patients with hepatocellular carcinoma awaiting liver transplantation should be treated with sofosbuvir in combination with ribavirin for treatment of chronic hepatitis C for weeks or until liver transplantation, whichever occurs first.
Dosing recommendations cannot be made for patients with severe renal impairment or end-stage renal disease.
Adverse reactions: The most common known adverse reactions (incidence rate equal to or greater than %, all grades) caused by sofosbuvir combined with ribavirin are headache and fatigue. Sofosbuvir combined with pegylated interferon h and ribavirin. The most common known adverse reactions include fatigue, headache, nausea, insomnia and anemia.
Drug Interactions: Potent intestinal glycoprotein inducers (such as rifampicin) may alter the plasma concentrations of sofosbuvir. Before use, please read the complete package insert for drug-drug interactions.
Medication for special groups: patients with H co-infection, the safety and effectiveness of this drug have been confirmed by research. Patients with hepatocellular carcinoma waiting for liver transplantation: the safety and effectiveness of this drug have been confirmed by research